Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Expression of B7-H1, a costimulating glycoprotein in the B7 family, is normally restricted to macrophage-lineage cells, providing a potential costimulatory signal source for regulation of T cell activation. In contrast, aberrant expression of B7-H1 by tumor cells has been implicated in impairment of T cell function and survival, resulting in defective host antitumoral immunity. The relationship between tumor-associated B7-H1 and clinical cancer progression is unknown. Herein, we report B7-H1 expression by both renal cell carcinoma (RCC) tumors of the kidney and RCC tumor-infiltrating lymphocytes. In addition, our analysis of 196 clinical specimens reveals that patients harboring high intratumoral expression levels of B7-H1, contributed by tumor cells alone, lymphocytes alone, or tumor and/or lymphocytes combined, exhibit aggressive tumors and are at markedly increased risk of death from RCC. In fact, patients with high tumor and/or lymphocyte B7-H1 levels are 4.5 times more likely to die from their cancer than patients exhibiting low levels of B7-H1 expression (risk ratio 4.53; 95% confidence interval 1.94–10.56; P < 0.001.) Thus, our study suggests a previously undescribed mechanism whereby RCC may impair host immunity to foster tumor progression. B7-H1 may prove useful as a prognostic variable for RCC patients both pre- and posttreatment. In addition, B7-H1 may represent a promising target to facilitate more favorable responses in patients who require immunotherapy for treatment of advanced RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subsequent human studies have consistently shown that PD-L1 and PD-L2 expression not only increases in cancerous tissues but is also linked to poor disease prognosis in many cancer types (50)(51)(52)(53)(54)(55)(56).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [50]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Self-citationIwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Self-citationPhan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
The Heidelberg classification of renal cell tumours
Kovacs, G., Akhtar, M., Beckwith, B. J., Bugert, P., Cooper, C. S., Delahunt, B., Eble, J. N., Fleming, S., Ljungberg, B., Medeiros, L. J., et al. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199710)183:2<131::aid-path931>3.0.co;2-g · Cited by 1,354
FRANK, I., BLUTE, M. L., CHEVILLE, J. C., LOHSE, C. M., WEAVER, A. L., & ZINCKE, H. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64153-5 · Cited by 1,175
Self-citationComparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma
Cheville, J. C., Lohse, C. M., Zincke, H., Weaver, A. L., & Blute, M. L. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200305000-00005 · Cited by 1,087
Self-citationHodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
THE CHANGING NATURAL HISTORY OF RENAL CELL CARCINOMA
PANTUCK, A. J., ZISMAN, A., & BELLDEGRUN, A. S. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65640-6 · Cited by 882
Research works printed but not linked: 13
- Strome, S.-E., Dong, H., Tamura, H., Voss, S.-G., Flies, D.-B., Tamada, K., Salomao, D., Cheville, J.-C, Hirano, F., Lin, W., et al. (2003) Cancer Res. 63, 6501–6505. [PubMed] [Google Scholar]
- Graham, S., Babayan, R.-K., Lamm, D.-L., Sawczuk, I., Ross, S.-D., Lavin, P.-T., Osband, M.-E. & Krane, R.-J. (1993) Semin. Urol. 11, 27–34. [PubMed] [Google Scholar]
- Krejci, K.-G., Markiewicz, M.-A. & Kwon, E.-D. (2003) J. Urol. 171, 870–876. [DOI] [PubMed] [Google Scholar]
- Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H. & Ohtani, H. (2001) Cancer Res. 61, 5132–5136. [PubMed] [Google Scholar]
- Storkel, S., Eble, J.-N., Adlakha, K., Amin, M., Blute, M.-L., Bostwick, D.-G., Darson, M., Delahunt, B. & Iczkowski, K. (1997) Cancer 80, 987–989. [DOI] [PubMed] [Google Scholar]
- Wintterle, S., Schreiner, B., Mitsdoerffer, M., Schneider, D., Chen, L., Meyermann, R., Weller, M. & Wiendl, H. (2003) Cancer Res. 63, 7462–7467. [PubMed] [Google Scholar]
- Uzzo, R.-G., Rayman, P., Kolenko, V., Clark, P.-E., Bloom, T., Ward, A.-M., Molto, L., Tannenbaum, C., Worford, L.-J, Bukowski, R.-M., et al. (1999) Clin. Cancer Res. 5, 1219–1229. [PubMed] [Google Scholar]
- Alexander, J.-P., Kudoh, S., Melsop, K.-A., Hamilton, T.-A., Edinger, M.-G., Tubbs, R.-R., Sica, D., Tuason, L., Klein, E., Bukowski, R., et al. (1993) Cancer. Res. 53, 1380–1387. [PubMed] [Google Scholar]
- Li, X., Liu, J., Park, J.-K., Hamilton, T.-A., Rayman, P., Klein, E., Edinger, M., Tubbs, R., Bukowski, R. & Finke, J. (1994) Cancer Res. 54, 5424–5429. [PubMed] [Google Scholar]
- Kudoh, S., Redovan, C., Rayman, P., Edinger, M., Tubbs, R.-R., Novick, A., Finke, J.-H. & Bukowski, R.-M. (1997) J. Immunol. 20, 479–487. [DOI] [PubMed] [Google Scholar]
- Motzer, R.-J. (2003) Crit. Rev. Oncol. Hematol. 46S, s33–s39. [DOI] [PubMed] [Google Scholar]
- Hofmockel, G., Tsatalpas, P., Muller, H., Dammrich, J., Poot, M., Maurer-Schultze, B., Muller-Hermelink, H.-K., Frohmuller, H.-G. & Bassukas, I.-D. (1995) Cancer 76, 296–306. [DOI] [PubMed] [Google Scholar]
- Shimazui, T., Oosterwijk, E., Akaza, H., Bringuier, P., Ruijter, E., van Berkel, H., Wakka, J.-O., van Bokhoven, A., Debruyne, F.-M. & Schalken, J.-A. (1998) Clin. Cancer Res. 4, 2419–2424. [PubMed] [Google Scholar]
Cited by
Items 401–500 of 796
Targeted therapy for renal cell carcinoma: The next lap
Tan, M.-H., & Kanesvaran, R. (2014) · Journal of Carcinogenesis · doi:10.4103/1477-3163.127638 · Cited by 32
Current status of prognostic factors in patients with metastatic renal cell carcinoma
Teishima, J., Inoue, S., Hayashi, T., & Matsubara, A. (2019) · International Journal of Urology · doi:10.1111/iju.13956 · Cited by 30
A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity
Kim, K., Yang, W., Jung, Y., & Cha, J. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.10.149 · Cited by 31
Programmed death ligand 1 (pd-l1) expression in malignant mesenchymal tumors
Kösemehmetoğlu, K., Özoğul, E., Babaoğlu, B., Tezel, G. G., & Gedikog̈lu, G. (2017) · Turkish Journal of Pathology · doi:10.5146/tjpath.2017.01395 · Cited by 29
Biomarker-Oriented Therapy in Bladder and Renal Cancer
Scholtes, M., Alberts, A. R., Iflé, I. G., Verhagen, P. C. M. S., van der Veldt, A. A. M., & Zuiverloon, T. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062832 · Cited by 30
Asgari, A., Lesyk, G. M., Poitras, E., Govindasamy, N. P., Terry, K., To, R. K., Back, V., Rudzinski, J. K., Lewis, J. D., & Jurasz, P. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15478 · Cited by 29
The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis
Chang, C., Shih, A. C.-C., Chang, Y.-H., Chen, H., Chao, Y., & Hsu, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759497 · Cited by 36
Ito, F., & Chang, A. E. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.005 · Cited by 38
Tarhini, A. A., Zahoor, H., Yearley, J. H., Gibson, C., Rahman, Z., Dubner, R. S., Rao, U. N. M., Sander, C., & Kirkwood, J. M. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0678-7 · Cited by 31
Reviving exhausted T lymphocytes during chronic virus infection by B7-H1 blockade
Yao, S., & Chen, L. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.04.007 · Cited by 30
Self-citationKamamoto, D., Ohara, K., Kitamura, Y., Yoshida, K., Kawakami, Y., & Sasaki, H. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2876-7 · Cited by 28
The Importance of Human Tissue Bioresources in Advancing Biomedical Research
Diffalha, S. A., Sexton, K. C., Watson, P. H., & Grizzle, W. E. (2019) · Biopreservation and Biobanking · doi:10.1089/bio.2019.0039 · Cited by 28
Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
Zhong, Z., Zhang, M., Ning, Y., Mao, G., Li, X., Deng, Q., Chen, X., Zuo, D., Zhao, X., Xie, E., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-22975-7 · Cited by 29
Ahmad, S. M., Borch, T. H., Hansen, M., & Andersen, M. H. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1783-4 · Cited by 30
Duc, G. H. T. (2014) · InTech eBooks · doi:10.5772/57004 · Cited by 28
Biomarkers in renal cell carcinoma: Are we there yet?
Gulati, S., & Vogelzang, N. J. (2021) · Asian journal of urology · doi:10.1016/j.ajur.2021.05.013 · Cited by 30
Wang, S., Park, S. H., Lim, J. S., Park, Y., Du, L., & Lee, J. (2022) · Genes & Genomics · doi:10.1007/s13258-022-01291-4 · Cited by 32
Coinhibitory molecules in cancer biology and therapy
Mocellin, S., Benna, C., & Pilati, P. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.01.003 · Cited by 29
Freeman-Keller, M., & Weber, J. S. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014551747 · Cited by 27
Prognostic and predictive biomarkers in renal cell carcinoma
Vickers, M. M., & Heng, D. Y. C. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0143-8 · Cited by 27
Anti-PD1 and Anti-PD-L1 in the Treatment of Metastatic Melanoma
Simeone, E., Grimaldi, A. M., & Ascierto, P. A. (2015) · Melanoma Management · doi:10.2217/mmt.14.30 · Cited by 27
Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials
Blick, C., Ritchie, A. W. S., Eisen, T., & Stewart, G. D. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.123 · Cited by 36
Lü, Y., Song, Y., Xu, Y., Ou, N., Liang, Z. C., Hu, R., Zhang, W., Kang, J., Wang, X., Liu, L., et al. (2020) · Translational Andrology and Urology · doi:10.21037/tau.2020.01.21 · Cited by 30
Tumour and patient factors in renal cell carcinoma—towards personalized therapy
Haddad, A., & Margulis, V. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.71 · Cited by 29
Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment
Zhang, Y., Sun, Z., Mao, X., Wu, H., Luo, F., Wu, X., Zhou, L., Qin, J., Zhao, L., & Bai, C. (2017) · Oncotarget · doi:10.18632/oncotarget.20241 · Cited by 28
Hayakawa, S. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.12.010 · Cited by 27
HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma
Zhang, Z., Cao, Y., Zhao, W., Guo, L., & Liu, W. (2017) · Cancer Biomarkers · doi:10.3233/cbm-160298 · Cited by 28
Anker, J. F., Miller, J. R., Taylor, N., Kyprianou, N., & Tsao, C. (2021) · Cells · doi:10.3390/cells10113231 · Cited by 28
Deutsch, J. S., Lipson, E. J., Danilova, L., Topalian, S. L., Jedrych, J. J., Baraban, E. G., Ged, Y. M. A., Singla, N., Choueiri, T. K., Gupta, S. K., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100947 · Cited by 27
Chen, Y., Zhang, J., Li, J., Zhao, T., Zou, L., Tang, Y., Zhang, X., & Wu, Y. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.026 · Cited by 26
Mechanisms of T-cell inhibition: implications for cancer immunotherapy
Mittendorf, E. A., & Sharma, P. (2010) · Expert Review of Vaccines · doi:10.1586/erv.09.144 · Cited by 27
TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer
Kato, R., Jinnouchi, N., Tuyukubo, T., Ikarashi, D., Matsuura, T., Maekawa, S., Kato, Y., Kanehira, M., Takata, R., Ishida, K., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100918 · Cited by 27
Inhibitory costimulation and anti-tumor immunity
Martín‐Orozco, N., & Dong, C. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.003 · Cited by 26
Park, S. H., Lee, J. H., Yun, H. J., Kim, S.-H., & Lee, J. (2024) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.0443 · Cited by 26
He, P., Ma, Z., Han, H., Zhang, X., Niu, S.-H., Du, L., Zheng, Y., & Liu, H. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117247 · Cited by 25
Emerging targets for anticancer vaccination: PD-1
Tobias, J., Steinberger, P., Drinić, M., & Wiedermann, U. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100278 · Cited by 26
Expected Paradigm Shift in Brain Metastases Therapy—Immune Checkpoint Inhibitors
Jindal, V., & Gupta, S. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0905-3 · Cited by 24
He, J., Huo, L., Ma, J., Zhao, J., Bassett, R. L., Sun, X., Ueno, N. T., Lim, B., & Gong, Y. (2017) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqx162 · Cited by 24
PD-1 Expression on Circulating CD8+ T-Cells as a Prognostic Marker for Patients With Gastric Cancer
Saito, H., Shimizu, S., Kono, Y., Murakami, Y., Shishido, Y., Miyatani, K., Matsunaga, T., Fukumoto, Y., Ashida, K., & Fujiwara, Y. (2018) · Anticancer Research · doi:10.21873/anticanres.13132 · Cited by 26
Palicelli, A., Bonacini, M., Croci, S., Magi‐Galluzzi, C., Cañete‐Portillo, S., Chaux, A., Bisagni, A., Zanetti, E., de Biase, D., Melli, B., et al. (2021) · Cells · doi:10.3390/cells10113165 · Cited by 24
Checkpoints and immunity in cancers: Role of GNG12
Alausa, A. O., Victor, U. C., Fadahunsi, O. S., Owolabi, N., Adeniji, A., Olatinwo, M., Ogunlana, A. T., Olaleke, B., Balogun, T. A., Ogundepo, S., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106242 · Cited by 25
Zhu, Q., Cai, M., Weng, D., Zhao, J., Pan, Q., Wang, Q., Tang, Y., He, J., Li, M., & Xia, J. (2019) · Journal of Cancer · doi:10.7150/jca.29052 · Cited by 26
PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness
Chang, K. S., Qu, Y., Dai, B., Zhao, J., Gan, H., Shi, G., Zhu, Y., Shen, Y., Zhu, Y., Zhang, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02005-7 · Cited by 26
Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities
Li, H.-Y., Chen, Y., Deng, X., Li, H., Tan, J., Liu, G., Zheng, Y., Pei, M., Peng, K.-T., Yue, L.-L., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01118-2 · Cited by 23
A twenty year perspective on melanoma therapy
Flaherty, K. T. (2023) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13125 · Cited by 23
Novel immunotherapy in metastatic renal cell carcinoma
Cho, Y. H., Kim, M. S., Chung, H. S., & Hwang, E. C. (2017) · Korean journal of urology · doi:10.4111/icu.2017.58.4.220 · Cited by 25
Potential role of the PD-L1 expression and tumor-infiltrating lymphocytes on neuroblastoma
Zuo, S., Sho, M., Sawai, T., Kanehiro, H., Maeda, K., Yoshida, M., Tsukada, R., Nomura, M., & Okuyama, H. (2020) · Pediatric Surgery International · doi:10.1007/s00383-019-04616-9 · Cited by 24
Mori, K., Quhal, F., Yanagisawa, T., Katayama, S., Pradère, B., Laukhtina, E., Rajwa, P., Mostafaei, H., Motlagh, R. S., Kimura, T., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108720 · Cited by 23
Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma
Qi, X., Jia, B., Zhao, X. B., & Yu, D. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s148182 · Cited by 22
Takei, J., Ohishi, T., Kaneko, M. K., Harada, H., Kawada, M., & Kato, Y. (2020) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2020.100801 · Cited by 22
Zhang, S., Qiujie, Y., Song, W., Feng, X., Xue, M., Liu, L., Cui, J., & Zhang, Y. (2021) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2021.02.019 · Cited by 25
Research progress on the intrinsic non‑immune function of PD‑L1 in tumors (Review)
Deng, J., Jiang, W., Liu, L., Zhan, W., Wu, Y., & Xu, X. S. (2022) · Oncology Letters · doi:10.3892/ol.2022.13596 · Cited by 22
Seo, S., Seo, D.-I., Park, W. S., Jung, W., Lee, D.-S., Park, S.-G., Choi, J. S., Kang, M., Choi, Y. H., Choi, I., et al. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.07.021 · Cited by 23
Liu, J., Quan, L., Zhang, C., Liu, A., Tong, D., & Wang, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.7682 · Cited by 22
Zhu, N., Weng, S., Wang, J., Chen, J., Yu, L., Fang, X., & Yuan, Y. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03044-5 · Cited by 22
Sabarwal, A., Chakraborty, S., Mahanta, S., Banerjee, S., Balan, M., & Pal, S. (2020) · Cancers · doi:10.3390/cancers12071782 · Cited by 22
GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma.
Yan, J., Zhou, B., Guo, L., Chen, Z., Zhang, B., Liu, S., Zhang, W., Yu, M., Xu, Y., Xiao, Y., et al. (2020) · PubMed Central · Cited by 26
KAUFFMAN, E. C., Liu, H., Schwartz, M. J., & Scherr, D. S. (2012) · Journal of Oncology · doi:10.1155/2012/103298 · Cited by 22
Cancer immunotherapy harnessing γδ T cells and programmed death‐1
Tanaka, Y. (2020) · Immunological Reviews · doi:10.1111/imr.12917 · Cited by 21
Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms
Almeida, S. D., Regimbeau, M., Jégo, G., Garrido, C., Girodon, F., & Hermetet, F. (2020) · Cancers · doi:10.3390/cancers12092592 · Cited by 21
Immune Therapy for Kidney Cancer: A Second Dawn?
McDermott, D. F., & Atkins, M. B. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.05.008 · Cited by 22
Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder
Owyong, M., Lotan, Y., Kapur, P., Panwar, V., McKenzie, T., Lee, T. K. M., Zi, X., Martin, J. W., Mosbah, A., Abol‐Enein, H., et al. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.02.017 · Cited by 21
Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma
Guo, C., Zhao, H., Wang, Y., Bai, S., Yang, Z., Wei, F., & Ren, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00439 · Cited by 23
Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook
Gedeon, P. C., Champion, C. D., Rhodin, K. E., Woroniecka, K. I., Kemeny, H. R., Bramall, A. N., Bernstock, J. D., Choi, B. D., & Sampson, J. H. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1817737 · Cited by 23
Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma
Ma, K., Qiao, Y., Wang, H., & Wang, S. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6486 · Cited by 21
State-of-the-Art Management of Renal Cell Carcinoma
Mourad, W. F., Dutcher, J. P., & Ennis, R. D. (2012) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31825d5522 · Cited by 23
Immune Checkpoint Inhibitors as Novel Targets for Renal Cell Carcinoma Therapeutics
Bailey, A. S., & McDermott, D. F. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e31829e3153 · Cited by 22
Blom, A. M., Gialeli, C., Hagerling, C., Berntsson, J., Jirström, K., & Παπαδάκος, Κ. Σ. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167659 · Cited by 20
PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
Ali, A. S., Langer, S. W., Federspiel, B., Hjortland, G. O., Grønbæk, H., Ladekarl, M. B., Welin, S., Vestermark, L. W., Arola, J. T., Osterlund, P. J., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243900 · Cited by 20
Bansal, A., Pandey, M. K., Barham, W. J., Liu, X., Harrington, S. M., Lucien, F., Dong, H., Park, S. S., & DeGrado, T. R. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.05.004 · Cited by 20
Self-citationCurrent status and future directions of molecular markers in renal cell carcinoma
Rini, B. I. (2006) · Current Opinion in Urology · doi:10.1097/01.mou.0000240304.96131.44 · Cited by 20
Surgical Treatment of Renal Cell Carcinoma in the Immunocompromised Transplant Patient
Tollefson, M. K., Krambeck, A. E., Leibovich, B. C., Blute, M. L., & Chow, G. K. (2009) · Urology · doi:10.1016/j.urology.2009.06.085 · Cited by 20
Self-citationHirata‐Nozaki, Y., Ohkuri, T., Ohara, K., Kumai, T., Nagata, M., Harabuchi, S., Kosaka, A., Nagato, T., Ishibashi, K., Oikawa, K., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1957-5 · Cited by 20
Modulation of Immune Response by B7 Family Molecules in Tumor Microenvironments
Flies, D. B., & Chen, L. (2006) · Immunological Investigations · doi:10.1080/08820130600755017 · Cited by 22
Self-citationSubverting the B7-H1/PD-1 Pathway in Advanced Melanoma and Kidney Cancer
Harshman, L. C., Choueiri, T. K., Drake, C. G., & Hodi, F. S. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000055 · Cited by 21
Καποδίστριας, Ν., Bobori, C., & Theocharopoulou, G. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-56246-9_18 · Cited by 19
Zhou, R., Li, Y., Liu, J., Wang, N., Huang, X., Cao, S.-R., & Shan, B. (2017) · Cancer Biomarkers · doi:10.3233/cbm-170269 · Cited by 19
PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer
Manson, Q. F., ter Hoeve, N. D., Buerger, H., Moelans, C. B., & van Diest, P. J. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0610-1 · Cited by 19
Eckel‐Passow, J. E., Ho, T. H., Serie, D., Cheville, J. C., Thompson, R. H., Costello, B. A., Dong, H., Kwon, E. D., Leibovich, B. C., & Parker, A. S. (2019) · Cancer Medicine · doi:10.1002/cam4.2769 · Cited by 20
Self-citationTrautmann, L., Said, E. A., Halwani, R., Janbazian, L., Chomont, N., Far, M. E., Breton, G., Haddad, E. K., & Sékaly, R. (2007) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3280ebb5c9 · Cited by 20
Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48
Xiao, J., Liu, J., Zhang, C., Liu, Z., Nie, Z., Yi, Z., Gao, X., Liang, H., Huang, J., Cai, Z., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011881 · Cited by 18
Nowicki, T. S., Anderson, J. L., & Federman, N. C. (2015) · Pediatric Research · doi:10.1038/pr.2015.246 · Cited by 18
Sabarwal, A., Wedel, J., Liu, K., Zurakowski, D., Chakraborty, S., Flynn, E. A., Briscoe, D. M., Balan, M., & Pal, S. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab126 · Cited by 18
The Emerging Role of Immunotherapy in Gastric and Esophageal Adenocarcinoma
Bockorny, B., & Pectasides, E. (2016) · Future Oncology · doi:10.2217/fon-2016-0103 · Cited by 19
Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice
Joseph, R. W., Chatta, G. S., & Vaishampayan, U. N. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.01.017 · Cited by 22
Bae, S. U., Jeong, W. K., Baek, S. K., Kim, N. K., & Hwang, I. (2018) · Oncology Letters · doi:10.3892/ol.2018.9264 · Cited by 21
Targeting PD-1 in cancer: Biological insights with a focus on breast cancer
Solinas, C., Aiello, M. M., Silva, P. D., Gu‐Trantien, C., Migliori, E., & Willard-Gallo, K. E. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.07.011 · Cited by 18
Piao, J., Lim, H. J., & Lee, M. (2020) · Obstetrics & Gynecology Science · doi:10.5468/ogs.2020.63.3.346 · Cited by 18
Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma
Fotia, G., Stellato, M., Guadalupi, V., Sepe, P., Claps, M., Giannatempo, P., Bottiglieri, A., Rametta, A., Taglialatela, I., Vela, C., et al. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01395-4 · Cited by 18
Ning, X., Gong, Y., He, S., Li, T., Wang, J., Peng, S., Chen, J.-C., Liu, J., Qi, N., Guo, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13765 · Cited by 19
Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
Cosso, F., Roviello, G., Nesi, G., Shabani, S., Spatafora, P., Villari, D., & Catalano, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044243 · Cited by 18
Li, D., Lan, X., Xu, L., Zhou, S., Luo, H., Zhang, X., Yu, W., Yang, Y., & Fang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1552010 · Cited by 20
Grzywnowicz, M., & Giannopoulos, K. (2012) · Acta Haematologica Polonica · doi:10.1016/s0001-5814(12)32008-2 · Cited by 21
Development of Novel Immune Interventions for Prostate Cancer
Agarwal, N., Padmanabh, S., & Vogelzang, N. J. (2012) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2012.01.012 · Cited by 19
Recent advances in the systemic treatment of metastatic non‐clear cell renal cell carcinomas
Ito, K. (2019) · International Journal of Urology · doi:10.1111/iju.14027 · Cited by 17
Guru, S. A., Sumi, M. P., Mir, R., Waza, A. A., Bhat, M. A., Zuberi, M., Lali, P., & Saxena, A. (2020) · Human Cell · doi:10.1007/s13577-020-00370-6 · Cited by 17
Takahara, T., Tsuyuki, T., Satou, A., Wada, E., Sakurai, K., Ueda, R., & Tsuzuki, T. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03256-6 · Cited by 18
Alwithenani, A., Bethune, D. C. G., Castonguay, M., Drucker, A., Flowerdew, G. J., Forsythe, M. L., French, D. G., Fris, J., Greer, W. L., Henteleff, H., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251080 · Cited by 17
Lessons learned in the surgical management of renal cell carcinoma
Sengupta, S., & Zincke, H. (2005) · Urology · doi:10.1016/j.urology.2005.06.004 · Cited by 17
Self-citationZheng, D., Hou, X., Yu, J., & He, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.928369 · Cited by 16
Metadata
- Authors
- Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., Zincke, H., Blute, M. L., Strome, S. E., Leibovich, B. C., & Kwon, E. D.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2004-11-29
- Volume
- 101
- Issue
- 49
- Pages
- 17174-17179
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC534606
- OpenAlex
- W4230861071
- Cited by
- 776
- References
- 48
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 15 · 2023: 29 · 2022: 32 · 2021: 42 · 2020: 51 · 2019: 60 · 2018: 57 · 2017: 76 · 2016: 65 · 2015: 69 · 2014: 57 · 2013: 29 · 2012: 28
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, renal cell carcinoma, tumor-infiltrating lymphocytes, tumor progression, prognostic factors, tumor immune evasion, T cell costimulation, immunotherapy targets, cancer mortality
- MeSH terms
- Carcinoma, Renal Cell, Follow-Up Studies, Humans, Immunity, Immunohistochemistry, Membrane Glycoproteins, Neoplasm Proteins, Peptides, Prognosis, Antigens, CD, Odds Ratio, Survival Analysis, Lymphocytes, Tumor-Infiltrating, B7-1 Antigen, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.